ThermoGenesis (THMO) 10-Q 12 Nov 20 2020 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 10, 2020
Document Information [Line Items]
Entity Registrant Name	ThermoGenesis Holdings, Inc.
Entity Central Index Key	0000811212
Trading Symbol	thmo
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		7,796,170
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Stock, $.001 par value

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 4,436,000	$ 3,157,000
Restricted cash		1,000,000
Accounts receivable, net of allowance for doubtful accounts of $220,000 ($226,000 at December 31, 2019)	1,698,000	1,278,000
Inventories, net of reserves of $755,000 ($350,000 at December 31, 2019)	5,876,000	3,824,000
Prepaid expenses and other current assets	766,000	602,000
Total current assets	12,776,000	9,861,000
Equipment and leasehold improvements, net	1,537,000	2,028,000
Right-of-use operating lease assets, net	765,000	859,000
Goodwill	781,000	781,000
Intangible assets, net	1,382,000	1,467,000
Other assets	48,000	218,000
Total assets	17,289,000	15,214,000
Current liabilities:
Accounts payable	1,661,000	1,447,000
Accrued payroll and related expenses	513,000	288,000
Deferred revenue – short-term	700,000	620,000
Interest payable – related party	1,519,000	1,869,000
Note payable – short-term	235,000
Other current liabilities	1,092,000	2,461,000
Total current liabilities	5,720,000	6,685,000
Convertible promissory note – related party, less debt discount of $4,893,000 ($5,195,000 at December 31, 2019)	5,107,000	3,518,000
Convertible promissory notes, less debt discount of $588,000 (plus debt premium of $46,000 at December 31, 2019)	412,000	413,000
Note payable	411,000	1,000,000
Operating lease obligations – long-term	648,000	761,000
Deferred revenue – long-term	1,669,000	1,901,000
Other noncurrent liabilities	20,000	20,000
Total liabilities	13,987,000	14,298,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding
Common stock, $0.001 par value; 350,000,000 shares authorized; 6,832,040 issued and outstanding (2,843,601 at December 31, 2019)	7,000	3,000
Additional paid in capital	253,537,000	237,313,000
Accumulated deficit	(250,434,000)	(236,932,000)
Accumulated other comprehensive loss	22,000	2,000
Total ThermoGenesis Holdings, Inc. stockholders’ equity	3,132,000	386,000
Noncontrolling interests	170,000	530,000
Total equity	3,302,000	916,000
Total liabilities and equity	$ 17,289,000	$ 15,214,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Accounts receivable, allowance for doubtful accounts	$ 220,000	$ 226,000
Inventories, reserves	755,000	350,000
Debt discount	$ 588,000	$ 46,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	6,832,040	2,843,601
Common stock, shares outstanding (in shares)	6,832,040	2,843,601
Convertible Promissory Note [Member]
Debt discount	$ 4,893,000	$ 5,195,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net revenues	$ 2,355,000	$ 4,058,000	$ 7,797,000	$ 11,325,000
Cost of revenues	844,000	2,163,000	7,426,000	6,220,000
Gross profit	1,511,000	1,895,000	371,000	5,105,000
Expenses:
Sales and marketing	539,000	502,000	1,424,000	1,227,000
Research and development	750,000	584,000	1,937,000	1,758,000
General and administrative	1,305,000	1,139,000	4,489,000	3,617,000
Total operating expenses	2,594,000	2,225,000	7,850,000	6,602,000
Loss from operations	(1,083,000)	(330,000)	(7,479,000)	(1,497,000)
Other income (expenses):
Interest expense	(1,531,000)	(1,188,000)	(6,377,000)	(3,531,000)
Loss on equity method investments			(13,000)
Loss on extinguishment of debt		(840,000)		(840,000)
Other income (expense)	5,000	(15,000)	7,000	(27,000)
Total other expense	(1,526,000)	(2,043,000)	(6,383,000)	(4,398,000)
Net loss	(2,609,000)	(2,373,000)	(13,862,000)	(5,895,000)
Loss attributable to noncontrolling interests	(146,000)	(91,000)	(360,000)	(445,000)
Net loss attributable to common stockholders	(2,463,000)	(2,282,000)	(13,502,000)	(5,450,000)
Net loss	(2,609,000)	(2,373,000)	(13,862,000)	(5,895,000)
Other comprehensive loss:
Foreign currency translation adjustments gain (loss)	(19,000)	16,000	20,000	9,000
Comprehensive loss	(2,628,000)	(2,357,000)	(13,842,000)	(5,886,000)
Comprehensive loss attributable to noncontrolling interests	(146,000)	(91,000)	(360,000)	(445,000)
Comprehensive loss attributable to common stockholders	$ (2,482,000)	$ (2,266,000)	$ (13,482,000)	$ (5,441,000)
Per share data:
Basic and diluted net loss per common share (in dollars per share)	$ (0.37)	$ (0.78)	$ (2.36)	$ (2)
Weighted average common shares outstanding basic and diluted (in shares)	6,711,664	2,913,198	5,728,105	2,720,502

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Equity (Unaudited) - USD ($)	Boyalife Investment Fund II, Inc. [Member]Common Stock [Member]	Boyalife Investment Fund II, Inc. [Member]Additional Paid-in Capital [Member]	Boyalife Investment Fund II, Inc. [Member]Retained Earnings [Member]	Boyalife Investment Fund II, Inc. [Member]AOCI Attributable to Parent [Member]	[1]	Boyalife Investment Fund II, Inc. [Member]Noncontrolling Interest [Member]	Boyalife Investment Fund II, Inc. [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	[1]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2018								2,168,337
Balance at Dec. 31, 2018								$ 2,000	$ 235,888,000	$ (227,435,000)	$ (13,000)		$ (1,711,000)	$ 6,731,000
Stock-based compensation expense									81,000					81,000
Exercise of pre-funded warrants (in shares)								50,000
Exercise of pre-funded warrants									5,000					5,000
Discount due to beneficial conversion features									1,513,000					1,513,000
Foreign currency translation gain (loss)											(4,000)			(4,000)
Net loss										(1,871,000)			(176,000)	(2,047,000)
Reorganization of subsidiary and related change in non-controlling interest									(2,843,000)				2,843,000
Balance (in shares) at Mar. 31, 2019								2,218,337
Balance at Mar. 31, 2019								$ 2,000	234,644,000	(229,306,000)	(17,000)		956,000	6,279,000
Balance (in shares) at Dec. 31, 2018								2,168,337
Balance at Dec. 31, 2018								$ 2,000	235,888,000	(227,435,000)	(13,000)		(1,711,000)	6,731,000
Foreign currency translation gain (loss)														9,000
Balance (in shares) at Sep. 30, 2019								2,704,837
Balance at Sep. 30, 2019								$ 3,000	236,830,000	(232,885,000)	(4,000)		687,000	4,631,000
Balance (in shares) at Mar. 31, 2019								2,218,337
Balance at Mar. 31, 2019								$ 2,000	234,644,000	(229,306,000)	(17,000)		956,000	6,279,000
Stock-based compensation expense									125,000					125,000
Exercise of pre-funded warrants (in shares)								150,000
Exercise of pre-funded warrants									18,000					18,000
Discount due to beneficial conversion features									800,000					800,000
Issuance of common stock, net									756,000					756,000
Foreign currency translation gain (loss)											(3,000)			(3,000)
Net loss										(1,297,000)			(178,000)	(1,475,000)
Balance (in shares) at Jun. 30, 2019								2,368,337
Balance at Jun. 30, 2019								$ 2,000	236,343,000	(230,603,000)	(20,000)		778,000	6,500,000
Stock-based compensation expense									253,000					253,000
Exercise of pre-funded warrants (in shares)								216,500
Exercise of pre-funded warrants								$ 1,000	18,000					19,000
Conversion of note payable to common stock (in shares)								120,000
Conversion of note payable to common stock									216,000					216,000
Foreign currency translation gain (loss)											16,000			16,000
Net loss										(2,282,000)			(91,000)	(2,373,000)
Balance (in shares) at Sep. 30, 2019								2,704,837
Balance at Sep. 30, 2019								$ 3,000	236,830,000	(232,885,000)	(4,000)		687,000	4,631,000
Balance (in shares) at Dec. 31, 2019								2,843,601
Balance at Dec. 31, 2019								$ 3,000	237,313,000	(236,932,000)	2,000		530,000	916,000
Stock-based compensation expense									67,000					67,000
Exercise of pre-funded warrants (in shares)								100,000
Exercise of pre-funded warrants									10,000					10,000
Exercise of warrants (in shares)								7,866
Exercise of warrants									47,000					47,000
Discount due to beneficial conversion features									1,869,000					1,869,000
Conversion of note payable to common stock (in shares)	1,666,670							100,000
Conversion of note payable to common stock	$ 2,000	$ 2,998,000					$ 3,000,000		180,000					180,000
Issuance of common stock, net (in shares)								1,050,748
Issuance of common stock, net								$ 1,000	3,220,000					3,221,000
Foreign currency translation gain (loss)											38,000			38,000
Net loss										(4,602,000)			(141,000)	(4,743,000)
Balance (in shares) at Mar. 31, 2020								5,768,885
Balance at Mar. 31, 2020								$ 6,000	245,704,000	(241,534,000)	40,000		389,000	4,605,000
Balance (in shares) at Dec. 31, 2019								2,843,601
Balance at Dec. 31, 2019								$ 3,000	237,313,000	(236,932,000)	2,000		530,000	916,000
Foreign currency translation gain (loss)														20,000
Balance (in shares) at Sep. 30, 2020								6,832,040
Balance at Sep. 30, 2020								$ 7,000	253,537,000	(250,434,000)	22,000		170,000	3,302,000
Balance (in shares) at Mar. 31, 2020								5,768,885
Balance at Mar. 31, 2020								$ 6,000	245,704,000	(241,534,000)	40,000		389,000	4,605,000
Stock-based compensation expense									314,000					314,000
Exercise of pre-funded warrants (in shares)								224,445
Exercise of pre-funded warrants									22,000					22,000
Exercise of warrants (in shares)								267,271
Exercise of warrants									1,604,000					1,604,000
Discount due to beneficial conversion features									3,112,000					3,112,000
Conversion of note payable to common stock (in shares)								104,445
Conversion of note payable to common stock								$ 1,000	188,000					189,000
Issuance of common stock, net (in shares)								344,419
Issuance of common stock, net									1,993,000					1,993,000
Foreign currency translation gain (loss)											1,000			1,000
Net loss										(6,437,000)			(73,000)	(6,510,000)
Balance (in shares) at Jun. 30, 2020								6,709,465
Balance at Jun. 30, 2020								$ 7,000	252,937,000	(247,971,000)	41,000		316,000	5,330,000
Stock-based compensation expense									234,000					234,000
Issuance of common stock, net (in shares)								122,575
Issuance of common stock, net									366,000					366,000
Foreign currency translation gain (loss)											(19,000)			(19,000)
Net loss										(2,463,000)			(146,000)	(2,609,000)
Balance (in shares) at Sep. 30, 2020								6,832,040
Balance at Sep. 30, 2020								$ 7,000	$ 253,537,000	$ (250,434,000)	$ 22,000		$ 170,000	$ 3,302,000
[1]	Accumulated other comprehensive loss.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (2,609,000)	$ (2,373,000)	$ (13,862,000)	$ (5,895,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			569,000	604,000
Stock based compensation expense			615,000	459,000
Amortization of debt discount/premium, net			2,165,000	1,799,000
Amortization of accelerated debt discount due to conversion			2,486,000
Reserve for excess and slow-moving inventories			4,036,000	141,000
Reserve for bad debt expense			(6,000)	(53,000)
Change in fair value derivative				2,000
Loss on disposal of equipment			118,000	20,000
Loss on extinguishment of debt		840,000		840,000
Net change in operating assets and liabilities:
Accounts receivable			(414,000)	(2,908,000)
Inventories			(6,086,000)	980,000
Prepaid expenses and other assets			6,000	(227,000)
Accounts payable			223,000	(542,000)
Interest payable - related party			(350,000)	(116,000)
Accrued payroll and related expenses			225,000	(298,000)
Deferred revenue – short-term			80,000	354,000
Other current liabilities			(1,326,000)	(145,000)
Long-term deferred revenue and other noncurrent liabilities			(338,000)	1,467,000
Net cash used in operating activities			(11,859,000)	(3,518,000)
Cash flows from investing activities:
Capital expenditures			(23,000)	(178,000)
Net cash used in investing activities			(23,000)	(178,000)
Cash flows from financing activities:
Proceeds from convertible promissory note-related party			4,287,000	1,513,000
Payments on financing lease obligations			(32,000)	(15,000)
Proceeds from issuance of common stock, net of expenses			5,580,000	756,000
Proceeds from exercise of options, warrants and pre-funded warrants			1,683,000	42,000
Proceeds from long-term debt				1,800,000
Proceeds from note payable			646,000
Net cash provided by financing activities			12,164,000	4,096,000
Effects of foreign currency rate changes on cash and cash equivalents			(3,000)
Net increase (decrease) in cash, cash equivalents and restricted cash			279,000	400,000
Cash, cash equivalents and restricted cash at beginning of period			4,157,000	3,400,000	$ 3,400,000
Cash, cash equivalents and restricted cash at end of period	$ 4,436,000	$ 3,800,000	4,436,000	3,800,000	$ 4,157,000
Supplemental disclosures of cash flow information:
Cash paid for interest			2,094,000	1,613,000
Supplemental non-cash financing and investing information:
Recording of beneficial conversion feature on debt			4,981,000	2,313,000
Right-to-use asset acquired under operating lease				966,000
Fair value of amended convertible note issued in connection with the extinguishment of original convertible note				1,473,000
Transfer of equipment to inventories				33,000
Conversion of Related Party Convertible Promissory Note Into Common Stock [Member]
Supplemental non-cash financing and investing information:
Promissory note converted to common stock			3,000,000
Conversion of January 2019 Amended Notes to Common Stock [Member]
Supplemental non-cash financing and investing information:
Promissory note converted to common stock			$ 369,000	$ 216,000

Note 1 - Description of Busines

Note 1 - Description of Business, Basis of Presentation and Going Concern	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. D ESCRIPTION OF B USINESS , B ASIS OF P RESENTATION AND GOING CONCERN Organization and Basis of Presentation ThermoGenesis Holdings, Inc. (“ThermoGenesis Holdings,” the “Company,” “we,” “our,” “us”) develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The Company was founded in 1986 The Company previously had two 2019, no no no two ® ® ® Clinical Bio-Banking Applications: ● AXP ® ● BioArchive ® Point-of-Care Applications: ● PXP ® Large Scale Cell Processing and Biomanufacturing: ● X ® X ® X ® X ® X ● CAR-TXpress™ Platform – a modular designed, functionally closed platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing and controls (“CMC”) needs for manufacturing chimeric antigen receptor (“CAR”) T cell therapies. CAR-TXpress Bio, Inc. (“CARTXpress Bio”) is owned and developed through a subsidiary in which we own 80% COVID- 19 ● Antibody Test – The ThermoGenesis SARS-CoV- 2 2 On January 1, 2019, July 2017 20% third 20% 80% 100% In the reorganization, the Company reacquired the non-controlling interest shares in ThermoGenesis Corp., which had an accumulated deficit of $1,711,000, 20% $1,100,000. $2,843,000 On November 26, 2019 80% 20% 18.79% ThermoGenesis Holdings is an affiliate of the Boyalife Group, a global diversified life science holding company that focuses on stem cell technology and cell-based therapeutics. Reverse Stock Split On June 4, 2019, one 1 ten 10 350,000,000 not Going Concern The Company has a Revolving Credit Agreement (“Credit Agreement”) with Boyalife Asset Holding II, Inc. (Refer to Note 3 $10,000,000 September 30, 2020, $10,000,000. On April 21, 2020, $646,000 $235,000 $411,000. two 1.00% first six may may At September 30, 2020, $4,436,000 $7,056,000. September 30, 2020 $250,434,000. one may may The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern; however, the above conditions raise substantial doubt about the Company's ability to do so. The condensed consolidated financial statements do not may Principles of Consolidation The consolidated financial statements include the accounts of ThermoGenesis Holdings and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp's majority-owned subsidiary, CARTXpress Bio. All significant intercompany accounts and transactions have been eliminated upon consolidation. Non-controlling Interests The 20% not 80% Interim Reporting The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. three nine September 30, 2020 not may December 31, 2020. 10 December 31, 2019.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Recently Issued Accounting Standards In August 2020, 2020 06 “Debt-Debt with Conversion and Other Options ( “ Subtopic 470 20 ” ) and Derivatives and Hedging—Contracts in Entity's Own Equity ( “ Subtopic 815 40 ” ): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity,” 1 2 3 may January 1, 2022 January 1, 2021. In December 2019, 2019 12 Income Taxes ( “ Topic 740 ” ): Simplifying the Accounting of Income Taxes , 2019 12 740 December 15, 2020, In June 2016, ASU 2016 13, “ Financial Instruments - Credit Losses ( “ Topic 326 ” ). ” 2016 13 December 15, 2022, not Recently Adopted Accounting Standards In August 2018, 2018 13, Fair Value Measurement (“Topic 820” not Revenue Recognition Revenue is recognized based on the five 606. The following tables summarize the revenues by product line: Three Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,137,000 $ 32,000 $ -- $ 1,169,000 BioArchive 337,000 282,000 -- 619,000 CAR-TXpress 332,000 22,000 71,000 425,000 Manual Disposables 100,000 -- -- 100,000 Other 26,000 -- 16,000 42,000 Total $ 1,932,000 $ 336,000 $ 87,000 $ 2,355,000 Nine Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,009,000 $ 103,000 $ -- $ 4,112,000 BioArchive 675,000 900,000 -- 1,575,000 CAR-TXpress 1,035,000 47,000 214,000 1,296,000 Manual Disposables 499,000 -- -- 499,000 Other 276,000 -- 39,000 315,000 Total $ 6,494,000 $ 1,050,000 $ 253,000 $ 7,797,000 Three Months Ended September 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 2,255,000 $ 51,000 $ -- $ 2,306,000 BioArchive 243,000 351,000 -- 594,000 Manual Disposables 221,000 -- -- 221,000 CAR-TXpress 875,000 10,000 33,000 918,000 Other -- -- 19,000 19,000 Total $ 3,594,000 $ 412,000 $ 52,000 $ 4,058,000 Nine Months Ended September 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 6,550,000 $ 160,000 $ -- $ 6,710,000 BioArchive 1,274,000 1,117,000 -- 2,391,000 Manual Disposables 764,000 -- -- 764,000 CAR-TXpress 1,365,000 6,000 33,000 1,404,000 Other 5,000 11,000 40,000 56,000 Total $ 9,958,000 $ 1,294,000 $ 73,000 $ 11,325,000 Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not three nine September 30, 2020 $115,000 $547,000, $620,000 $700,000 $1,901,000 $1,669,000 nine September 30, 2020, Exclusivity Fee On August 30, 2019, five two X ® $2,000,000 The Company performed an evaluation of the revenue recognition of the $2,000,000 606. $2,000,000 one two five seven seven three nine September 30, 2020, $71,000 $214,000, $2,000,000 $1,690,000 $286,000 $1,404,000 Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2020 2021 2022 2023 2024 and beyond Total Service revenue $ 310,000 $ 958,000 $ 561,000 $ 298,000 $ 38,000 $ 2,165,000 Clinical revenue 3,000 13,000 13,000 13,000 175,000 217,000 Exclusivity fee 71,000 286,000 286,000 286,000 761,000 1,690,000 Total $ 384,000 $ 1,257,000 $ 860,000 $ 597,000 $ 974,000 $ 4,072,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues. Fair Value Measurements In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs which are supported by little or no The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company's derivative obligation liability is classified as Level 3 not 3 Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no September 30, 2020, none September 30: 2020 2019 Common stock equivalents of convertible promissory note and accrued interest 6,988,334 6,013,667 Vested Series A warrants 40,441 40,441 Unvested Series A warrants (1) 69,853 69,853 Warrants – other 1,006,190 1,300,091 Stock options 892,149 296,029 Total 8,996,967 7,720,081 ___________ ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not

Note 3 - Related Party Transact

Note 3 - Related Party Transactions	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	3. Related Party Transactions Health B anks Biotech (USA) Inc. On November 26, 2019 80% 20% 18.79% first 115% 2018 no $1,000,000 Between November 26, 2019 September 30, 2020, $3,700,000 643,750 $5.00 $16.00 6.05% no 75.16% 18.79% 6.05% The Company initially determined that ImmuneCyte would be considered a variable interest entity, as a result of the significant influence the Company has over operations and its' lack of sufficient equity at inception. After the additional investment of $3,700,000, no $28,000, The Company entered into a supply agreement with ImmuneCyte with an effective date of April 22, 2020. 19 one thirty 30 $3,600,000 nine September 30, 2020. August 2020, $800,000 September 30, 2020. nine September 30, 2020, September 30, 2020 $2,800,000. 19 August 2020 For the three nine September 30, 2020, $0 $13,000, September 30, 2020, $0. three nine September 30, 2020, $1,313,000 $1,422,000, September 30, 2020, $2,120,000 $296,000. Convertible Promissory Note and Revolving Credit Agreement In March 2017, $10,000,000 March 6, 2022 ( February 2020, $1,869,000 $3,000,000 1,666,670 two $2,486,000 April 28, 2020, $2,418,000 $10,000,000 $580,000. 2 19 September 30, 2020, $10,000,000. The Credit Agreement and the Convertible Promissory Note issued thereunder (the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% five The Maturity Date of the Note is subject to acceleration at the option of the Lender upon customary events of default, which include; a breach of the Loan documents, termination of operations, or bankruptcy. The Lender's obligation to make advances under the Loan is subject to the Company's representations and warranties in the Credit Agreement continuing to be true at all times and there being no The Credit Agreement and Note were amended in April 2018. $16.10 two 2018, $1.80. It was concluded that the conversion option of the draw down in February 2020 $1,869,000 March 31, 2020. April 2020 $2,418,000 June 30, 2020. $828,000 $2,103,000 three nine September 30, 2020, $471,000 $1,398,000 three nine September 30, 2019, September 30, 2020, $1,519,000 $1,869,000 December 31, 2019 Distributor Agreement On August 21, 2017, ® ® ® ® ® The term of the agreement is for three two During the three nine September 30, 2020, no three nine September 30, 2019, $214,000 $794,000,

Note 4 - Convertible Promissory

Note 4 - Convertible Promissory Note	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	4. CONVERTIBLE PROMISSORY NOTE On January 29, 2019, $800,000 “January 2019 six $1.80 90% $0.50 The January 2019 twenty-four 24% January 2019 eighteen 18 January 2019 January 2019 may On the date that is six January 2019 January 2019 January 2019 may January 2019 January 2019 4.99% 9.99% $800,000, May 30, 2019. On July 23, 2019, No. 1 January 2019 January 2019 July 29, 2020 July 31, 2022. January 2019 January 2019 January 2019 10% January 2019 $840,000 December 31, 2019. $1,473,000 $556,000 December 31, 2019. $77,000 January 2019 December 31, 2019. During the nine September 30, 2020, nine September 30, 2020, $369,000 204,445 $46,000 nine September 30, 2020. On July 23, 2019, $1,000,000 “July 2019 $1.80 90% $0.50 July 2019 twenty-four 24% July 2019 three July 31, 2022. The July 2019 may six July 2019 may July 2019 July 2019 $694,000, June 4, 2020. July 2019 three nine September 30, 2020, $27,000 $107,000,

Note 5 - Leases

Note 5 - Leases	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	5 . LEASES The Company leases the Rancho Cordova, California and Gurgaon, India facilities pursuant to operating leases. The Rancho Cordova lease expires in May 2024. September 2023; three Operating Leases Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not not The following summarizes the Company's operating leases: September 30, 2020 Right-of-use operating lease assets, net $ 765,000 Current lease liability 147,000 Non-current lease liability 648,000 Weighted average remaining lease term 3.7 Discount rate 22 % Maturities of lease liabilities by year for our operating leases are as follows: 2020 (remaining) $ 76,000 2021 310,000 2022 319,000 2023 328,000 2024 139,000 Thereafter -- Total lease payments $ 1,172,000 Less: imputed interest (377,000 ) Present value of operating lease liabilities $ 795,000 Statement of Cash Flows In January 2019, $966,000 $225,000 nine September 30, 2020 Operating Lease Costs Operating lease costs were $135,000 $343,000 three nine September 30, 2020, 30 Finance Leases Finance leases are included in equipment and other current and non-current liabilities on the condensed consolidated balance sheet. The amortization and interest expense are included in general and administrative expense and interest expense, respectively on the statement of operations. These leases are not not three nine September 30, 2020.

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	6 . COMMITMENTS AND CONTINGENCIES Financial Covenants Effective March 16, 2020, #1 May 15, 2017 $2.0 $1.0 one On July 13, 2020, #2 July 13, 2020 ( one $1,000,000 The Company was in compliance with this financial covenant as of September 30, 2020. Warranty The Company offers a warranty on all of its non-disposable products of one two The warranty liability is included in other current liabilities in the unaudited condensed consolidated balance sheets. The change in the warranty liability for the nine September 30, 2020 Balance at December 31, 2019 $ 277,000 Warranties issued during the period 62,000 Settlements made during the period (171,000 ) Changes in liability for pre-existing warranties during the period (20,000 ) Balance at September 30, 2020 $ 148,000 Contingen cies and Restricted Cash In fiscal 2016, May 4, 2017, $1,000,000 August 2016. October 2017, $1,000,000 February 2020 $1,000,000. $1,400,000 December 31, 2019. $1,000,000 $400,000 $1,000,000 no April 2020, May 1, 2020 $480,000, $369,000 $111,000 not $1,000,000 In the normal course of operations, the Company may September 30, 2020, may not

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	7 . STOCKHOLDERS' EQUITY Common Stock On March 25, 2020, three 1,000,002 $3.50 $3.5 $393,000 3 No. 333 235509 December 13, 2019 January 3, 2020, March 27, 2020. March 27, 2020. 30 twelve 12 On December 13, 2019, may $4.4 May 19, 2020 $15,280,313 3 No. 333 235509 may 415 1933, may not August 9, 2022. 3% September 30, 2020, 517,740 $2,785,000 $5.38 $2,473,000 $312,000. Subsequent to September 30, 2020, 964,130 $2,771,000 $2.87 $2,683,000 $88,000. Stock Based Compensation The Company recorded stock-based compensation of $234,000 $615,000 three nine September 30, 2020, $253,000 $459,000 three nine September 30, 2019, Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Cost of revenues $ 3,000 $ 1,000 $ 5,000 $ 2,000 Sales and marketing 65,000 110,000 106,000 166,000 Research and development 36,000 38,000 72,000 75,000 General and administrative 130,000 104,000 432,000 216,000 Total $ 234,000 $ 253,000 $ 615,000 $ 459,000 The following is a summary of option activity for the Company's stock option plans: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2019 291,807 $ 13.96 Granted 615,500 $ 5.92 Forfeited (15,158 ) $ 5.13 Outstanding at September 30, 2020 892,149 $ 8.57 8.997 $ -- Vested and expected to vest at September 30, 2020 565,836 $ 9.91 8.736 $ -- Exercisable at September 30, 2020 184,137 $ 17.05 7.665 $ -- The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company's common stock. There were no nine September 30, 2020. Warrants A summary of warrant activity for the nine September 30, 2020 Number of Shares Weighted-Average Exercise Price Per Share Balance at December 31, 2019 1,716,066 $ 25.23 Warrants expired -- -- Warrants exercised (599,582 ) $ 2.81 Outstanding at September 30, 2020 1,116,484 $ 37.27 Exercisable at September 30, 2020 1,046,631 $ 34.42

Note 8 - Major Customers and Ac

Note 8 - Major Customers and Accounts Receivable	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	8 . MAJOR CUSTOMERS AND ACCOUNTS RECEIVABLE The Company had certain customers whose revenue individually represented 10% 10% For the three September 30, 2020 2019, one 22% 27% second 20% 13% third 10% 2% nine September 30, 2020 2019, one 28% 29% second 12% 13% third 12% 0% At September 30, 2020, two 59% December 31, 2019, three 53%

Note 9 - Subsequent Events

Note 9 - Subsequent Events	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	9 . S UBSEQUENT EVENTS The Company has evaluated events subsequent to the balance sheet date for inclusion in the accompanying consolidated financial statements through the date of issuance and determined that no

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Standards In August 2020, 2020 06 “Debt-Debt with Conversion and Other Options ( “ Subtopic 470 20 ” ) and Derivatives and Hedging—Contracts in Entity's Own Equity ( “ Subtopic 815 40 ” ): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity,” 1 2 3 may January 1, 2022 January 1, 2021. In December 2019, 2019 12 Income Taxes ( “ Topic 740 ” ): Simplifying the Accounting of Income Taxes , 2019 12 740 December 15, 2020, In June 2016, ASU 2016 13, “ Financial Instruments - Credit Losses ( “ Topic 326 ” ). ” 2016 13 December 15, 2022, not Recently Adopted Accounting Standards In August 2018, 2018 13, Fair Value Measurement (“Topic 820” not
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Revenue is recognized based on the five 606. The following tables summarize the revenues by product line: Three Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,137,000 $ 32,000 $ -- $ 1,169,000 BioArchive 337,000 282,000 -- 619,000 CAR-TXpress 332,000 22,000 71,000 425,000 Manual Disposables 100,000 -- -- 100,000 Other 26,000 -- 16,000 42,000 Total $ 1,932,000 $ 336,000 $ 87,000 $ 2,355,000 Nine Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,009,000 $ 103,000 $ -- $ 4,112,000 BioArchive 675,000 900,000 -- 1,575,000 CAR-TXpress 1,035,000 47,000 214,000 1,296,000 Manual Disposables 499,000 -- -- 499,000 Other 276,000 -- 39,000 315,000 Total $ 6,494,000 $ 1,050,000 $ 253,000 $ 7,797,000 Three Months Ended September 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 2,255,000 $ 51,000 $ -- $ 2,306,000 BioArchive 243,000 351,000 -- 594,000 Manual Disposables 221,000 -- -- 221,000 CAR-TXpress 875,000 10,000 33,000 918,000 Other -- -- 19,000 19,000 Total $ 3,594,000 $ 412,000 $ 52,000 $ 4,058,000 Nine Months Ended September 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 6,550,000 $ 160,000 $ -- $ 6,710,000 BioArchive 1,274,000 1,117,000 -- 2,391,000 Manual Disposables 764,000 -- -- 764,000 CAR-TXpress 1,365,000 6,000 33,000 1,404,000 Other 5,000 11,000 40,000 56,000 Total $ 9,958,000 $ 1,294,000 $ 73,000 $ 11,325,000 Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not three nine September 30, 2020 $115,000 $547,000, $620,000 $700,000 $1,901,000 $1,669,000 nine September 30, 2020, Exclusivity Fee On August 30, 2019, five two X ® $2,000,000 The Company performed an evaluation of the revenue recognition of the $2,000,000 606. $2,000,000 one two five seven seven three nine September 30, 2020, $71,000 $214,000, $2,000,000 $1,690,000 $286,000 $1,404,000 Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2020 2021 2022 2023 2024 and beyond Total Service revenue $ 310,000 $ 958,000 $ 561,000 $ 298,000 $ 38,000 $ 2,165,000 Clinical revenue 3,000 13,000 13,000 13,000 175,000 217,000 Exclusivity fee 71,000 286,000 286,000 286,000 761,000 1,690,000 Total $ 384,000 $ 1,257,000 $ 860,000 $ 597,000 $ 974,000 $ 4,072,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Measurements In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs which are supported by little or no The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company's derivative obligation liability is classified as Level 3 not 3
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no September 30, 2020, none September 30: 2020 2019 Common stock equivalents of convertible promissory note and accrued interest 6,988,334 6,013,667 Vested Series A warrants 40,441 40,441 Unvested Series A warrants (1) 69,853 69,853 Warrants – other 1,006,190 1,300,091 Stock options 892,149 296,029 Total 8,996,967 7,720,081 ___________ ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021.
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,137,000 $ 32,000 $ -- $ 1,169,000 BioArchive 337,000 282,000 -- 619,000 CAR-TXpress 332,000 22,000 71,000 425,000 Manual Disposables 100,000 -- -- 100,000 Other 26,000 -- 16,000 42,000 Total $ 1,932,000 $ 336,000 $ 87,000 $ 2,355,000 Nine Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,009,000 $ 103,000 $ -- $ 4,112,000 BioArchive 675,000 900,000 -- 1,575,000 CAR-TXpress 1,035,000 47,000 214,000 1,296,000 Manual Disposables 499,000 -- -- 499,000 Other 276,000 -- 39,000 315,000 Total $ 6,494,000 $ 1,050,000 $ 253,000 $ 7,797,000 Three Months Ended September 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 2,255,000 $ 51,000 $ -- $ 2,306,000 BioArchive 243,000 351,000 -- 594,000 Manual Disposables 221,000 -- -- 221,000 CAR-TXpress 875,000 10,000 33,000 918,000 Other -- -- 19,000 19,000 Total $ 3,594,000 $ 412,000 $ 52,000 $ 4,058,000 Nine Months Ended September 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 6,550,000 $ 160,000 $ -- $ 6,710,000 BioArchive 1,274,000 1,117,000 -- 2,391,000 Manual Disposables 764,000 -- -- 764,000 CAR-TXpress 1,365,000 6,000 33,000 1,404,000 Other 5,000 11,000 40,000 56,000 Total $ 9,958,000 $ 1,294,000 $ 73,000 $ 11,325,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	Remainder of 2020 2021 2022 2023 2024 and beyond Total Service revenue $ 310,000 $ 958,000 $ 561,000 $ 298,000 $ 38,000 $ 2,165,000 Clinical revenue 3,000 13,000 13,000 13,000 175,000 217,000 Exclusivity fee 71,000 286,000 286,000 286,000 761,000 1,690,000 Total $ 384,000 $ 1,257,000 $ 860,000 $ 597,000 $ 974,000 $ 4,072,000
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2020 2019 Common stock equivalents of convertible promissory note and accrued interest 6,988,334 6,013,667 Vested Series A warrants 40,441 40,441 Unvested Series A warrants (1) 69,853 69,853 Warrants – other 1,006,190 1,300,091 Stock options 892,149 296,029 Total 8,996,967 7,720,081

Note 5 - Leases (Tables)

Note 5 - Leases (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Lease, Cost [Table Text Block]	September 30, 2020 Right-of-use operating lease assets, net $ 765,000 Current lease liability 147,000 Non-current lease liability 648,000 Weighted average remaining lease term 3.7 Discount rate 22 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2020 (remaining) $ 76,000 2021 310,000 2022 319,000 2023 328,000 2024 139,000 Thereafter -- Total lease payments $ 1,172,000 Less: imputed interest (377,000 ) Present value of operating lease liabilities $ 795,000

Note 6 - Commitments and Cont_2

Note 6 - Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Product Warranty Liability [Table Text Block]	Balance at December 31, 2019 $ 277,000 Warranties issued during the period 62,000 Settlements made during the period (171,000 ) Changes in liability for pre-existing warranties during the period (20,000 ) Balance at September 30, 2020 $ 148,000

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Cost of revenues $ 3,000 $ 1,000 $ 5,000 $ 2,000 Sales and marketing 65,000 110,000 106,000 166,000 Research and development 36,000 38,000 72,000 75,000 General and administrative 130,000 104,000 432,000 216,000 Total $ 234,000 $ 253,000 $ 615,000 $ 459,000
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2019 291,807 $ 13.96 Granted 615,500 $ 5.92 Forfeited (15,158 ) $ 5.13 Outstanding at September 30, 2020 892,149 $ 8.57 8.997 $ -- Vested and expected to vest at September 30, 2020 565,836 $ 9.91 8.736 $ -- Exercisable at September 30, 2020 184,137 $ 17.05 7.665 $ --
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Weighted-Average Exercise Price Per Share Balance at December 31, 2019 1,716,066 $ 25.23 Warrants expired -- -- Warrants exercised (599,582 ) $ 2.81 Outstanding at September 30, 2020 1,116,484 $ 37.27 Exercisable at September 30, 2020 1,046,631 $ 34.42

Note 1 - Description of Busin_2

Note 1 - Description of Business, Basis of Presentation and Going Concern (Details Textual)	Apr. 21, 2020USD ($)	Jun. 04, 2019shares	Jan. 01, 2019USD ($)	Mar. 31, 2019USD ($)	Sep. 30, 2020USD ($)shares	Jun. 30, 2020	Apr. 28, 2020USD ($)	Dec. 31, 2019USD ($)shares	Nov. 26, 2019USD ($)	Mar. 31, 2017USD ($)
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance					$ 170,000			$ 530,000
Reorganization of Subsidiary and Related Change in Non-controlling Interest
Common Stock, Shares Authorized (in shares) | shares		350,000,000			350,000,000			350,000,000
Notes Payable, Current, Total					$ 235,000
Notes Payable, Noncurrent, Total					411,000			1,000,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance					4,436,000			3,157,000
Working Capital					7,056,000
Retained Earnings (Accumulated Deficit), Ending Balance					(250,434,000)			$ (236,932,000)
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Long-term Debt, Total	$ 646,000
Notes Payable, Current, Total					235,000
Notes Payable, Noncurrent, Total					411,000
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity					10,000,000					$ 10,000,000
Long-term Line of Credit, Total					$ 10,000,000		$ 10,000,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		10
ImmuneCyte [Member]
Equity Method Investment, Ownership Percentage					18.79%				20.00%
Line of Credit Facility, Maximum Borrowing Capacity									$ 1,000,000
ImmuneCyte [Member] | HealthBanks Biotech [Member]
Equity Method Investment, Ownership Percentage					75.16%				80.00%
Noncontrolling Interest [Member]
Reorganization of Subsidiary and Related Change in Non-controlling Interest			$ 2,843,000	$ 2,843,000
CAR-TXpress [Member]
Noncontrolling Interest, Ownership Percentage by Parent			80.00%		80.00%	80.00%
Minority Interest Acquired Through Exchange			20.00%
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance			$ 1,100,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners						20.00%
ThermoGenesis [Member]
Noncontrolling Interest, Ownership Percentage by Parent			100.00%
Ownership in Subsidiary Exchanged			20.00%
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance			$ (1,711,000)

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Aug. 30, 2019	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Contract with Customer, Liability, Revenue Recognized		$ 115,000	$ 547,000
Deferred Revenue, Current, Total		700,000	700,000	$ 620,000
Deferred Revenue, Noncurrent, Total		1,669,000	1,669,000	$ 1,901,000
Exclusivity Fee [Member]
Deferred Revenue, Current, Total		286,000	286,000
Deferred Revenue, Noncurrent, Total		1,404,000	1,404,000
Deferred Revenue, Total		1,690,000	1,690,000
Exclusivity Fee [Member]
Contract with Customer, Liability, Revenue Recognized		$ 71,000	$ 214,000
Exclusivity Fee Recognize Period (Year)			7 years
Supply Agreement [Member]
Supply Agreement, Term (Year)	5 years
Supply Agreement, Renewal Term (Year)	2 years		2 years
Contract with Customer, Liability, Total	$ 2,000,000
Proceeds from Customers			$ 2,000,000

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Revenues (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net revenues	$ 2,355,000	$ 4,058,000	$ 7,797,000	$ 11,325,000
Device [Member] | AXP [Member]
Net revenues	1,169,000	2,306,000	4,112,000	6,710,000
Device [Member] | BioArchive [Member]
Net revenues	619,000	594,000	1,575,000	2,391,000
Device [Member] | CAR-TXpress [Member]
Net revenues	425,000	918,000	1,296,000	1,404,000
Device [Member] | Manual Disposables [Member]
Net revenues	100,000	221,000	499,000	764,000
Device [Member] | Other Subsegments [Member]
Net revenues	42,000	19,000	315,000	56,000
Device Revenue [Member]
Net revenues	1,932,000	3,594,000	6,494,000	9,958,000
Device Revenue [Member] | Device [Member] | AXP [Member]
Net revenues	1,137,000	2,255,000	4,009,000	6,550,000
Device Revenue [Member] | Device [Member] | BioArchive [Member]
Net revenues	337,000	243,000	675,000	1,274,000
Device Revenue [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	332,000	875,000	1,035,000	1,365,000
Device Revenue [Member] | Device [Member] | Manual Disposables [Member]
Net revenues	100,000	221,000	499,000	764,000
Device Revenue [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	26,000		276,000	5,000
Service [Member]
Net revenues	336,000	412,000	1,050,000	1,294,000
Service [Member] | Device [Member] | AXP [Member]
Net revenues	32,000	51,000	103,000	160,000
Service [Member] | Device [Member] | BioArchive [Member]
Net revenues	282,000	351,000	900,000	1,117,000
Service [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	22,000	10,000	47,000	6,000
Service [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Service [Member] | Device [Member] | Other Subsegments [Member]
Net revenues				11,000
Other [Member]
Net revenues	87,000	52,000	253,000	73,000
Other [Member] | Device [Member] | AXP [Member]
Net revenues
Other [Member] | Device [Member] | BioArchive [Member]
Net revenues
Other [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	71,000	33,000	214,000	33,000
Other [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Other [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	$ 16,000	$ 19,000	$ 39,000	$ 40,000

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details)	Sep. 30, 2020USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 4,072,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	2,165,000
Clinical Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	217,000
Exclusivity Fee [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,690,000

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations 2 (Details)	Sep. 30, 2020USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 4,072,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	91 days
Revenue, Remaining Performance Obligation, Amount	$ 384,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 1,257,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 860,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 597,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 974,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	$ 2,165,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	91 days
Revenue, Remaining Performance Obligation, Amount	$ 310,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 958,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 561,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 298,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 38,000
Clinical Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	$ 217,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	91 days
Revenue, Remaining Performance Obligation, Amount	$ 3,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 175,000
Exclusivity Fee [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,690,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	91 days
Revenue, Remaining Performance Obligation, Amount	$ 71,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 761,000

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares		9 Months Ended
		Sep. 30, 2020	Sep. 30, 2019
Anti-dilutive securities (in shares)		8,996,967	7,720,081
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)		6,988,334	6,013,667
Vested Series A Warrants [Member]
Anti-dilutive securities (in shares)		40,441	40,441
Unvested Series A Warrants [Member]
Anti-dilutive securities (in shares)	[1]	69,853	69,853
Warrant, Other [Member]
Anti-dilutive securities (in shares)		1,006,190	1,300,091
Share-based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)		892,149	296,029
[1]	The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021.

Note 3 - Related Party Transa_2

Note 3 - Related Party Transactions (Details Textual) - USD ($)	Apr. 28, 2020	Feb. 29, 2020	Aug. 21, 2017	Feb. 29, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Dec. 31, 2019	Nov. 26, 2019	Dec. 31, 2018	Apr. 16, 2018	Mar. 31, 2017
Income (Loss) from Equity Method Investments, Total							$ (13,000)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total					(2,609,000)	(2,373,000)	(13,862,000)	(5,895,000)
Assets, Current, Total					12,776,000		12,776,000		$ 12,776,000	$ 9,861,000
Liabilities, Current, Total					5,720,000		5,720,000		5,720,000	6,685,000
Amortization of Accelerated Debt Discount Due to Conversion							2,486,000
Amortization of Debt Discount (Premium)							2,165,000	1,799,000
Conversion of Related Party Convertible Promissory Note Into Common Stock [Member]
Debt Conversion, Original Debt, Amount				$ 3,000,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)				1,666,670
Boyalife Investment Fund II, Inc. [Member] | Convertible Debt [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)												$ 1.80	$ 16.10
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity					10,000,000		10,000,000		10,000,000					$ 10,000,000
Proceeds from Long-term Lines of Credit	$ 2,418,000			$ 1,869,000
Amortization of Accelerated Debt Discount Due to Conversion				$ 2,486,000
Long-term Line of Credit, Total	10,000,000				10,000,000		10,000,000		10,000,000
Interest Payable	$ 580,000				$ 1,519,000		$ 1,519,000		$ 1,519,000	$ 1,869,000
Debt Instrument, Interest Rate, Stated Percentage					22.00%		22.00%		22.00%
Debt Instrument, Convertible, Beneficial Conversion Feature		$ 1,869,000
Amortization of Debt Discount (Premium)					$ 828,000	471,000	$ 2,103,000	1,398,000
Boyalife W.S.N. [Member]
Distributor Agreement Term (Year)			3 years
Distributor Agreement, Renewal Term (Year)			2 years
Revenue from Related Parties					0	$ 214,000	0	$ 794,000
COVID-19 Testing Kits [Member]
Inventory Write-down							2,800,000
COVID-19 Testing Kits [Member] | ImmuneCyte [Member]
Related Party Transaction, Purchases from Related Party							$ 3,600,000
Refund from Related Party Purchases					$ 800,000
ImmuneCyte [Member]
Proceeds from Issuance of Common Stock									$ 3,700,000
ImmuneCyte [Member] | Common Class A [Member]
Stock Issued During Period, Shares, New Issues (in shares)									643,750
ImmuneCyte [Member] | Common Class A [Member] | Minimum [Member]
Shares Issued, Price Per Share (in dollars per share)					$ 5		$ 5		$ 5
ImmuneCyte [Member] | Common Class A [Member] | Maximum [Member]
Shares Issued, Price Per Share (in dollars per share)					$ 16		$ 16		$ 16
ImmuneCyte [Member]
Equity Method Investment, Ownership Percentage					18.79%		18.79%		18.79%		20.00%
Joint Venture Purchase, Percent of Company's Cost											115.00%
Line of Credit Facility, Maximum Borrowing Capacity											$ 1,000,000
Equity Method Investment, Aggregate Cost					$ 0		$ 0		$ 0		$ 28,000
Income (Loss) from Equity Method Investments, Total					0		13,000
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total					1,313,000		1,422,000
Assets, Current, Total					2,120,000		2,120,000		2,120,000
Liabilities, Current, Total					$ 296,000		$ 296,000		$ 296,000
ImmuneCyte [Member] | HealthBanks Biotech [Member]
Equity Method Investment, Ownership Percentage					75.16%		75.16%		75.16%		80.00%
ImmuneCyte [Member] | Private Institution [Member]
Equity Method Investment, Ownership Percentage					6.05%		6.05%		6.05%

Note 4 - Convertible Promisso_2

Note 4 - Convertible Promissory Note (Details Textual) - USD ($)	Jun. 04, 2020	Jul. 23, 2019	Jan. 29, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	May 30, 2019
Gain (Loss) on Extinguishment of Debt, Total					$ (840,000)		$ (840,000)
Amortization of Debt Discount (Premium)						2,165,000	$ 1,799,000
Conversion of Convertible Promissory Note to Common Stock [Member]
Debt Conversion, Converted Instrument, Amount						$ 369,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)						204,445
Interest Income (Expense), Nonoperating, Net						$ 46,000
Convertible Debt [Member] | Notes [Member]
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger			90.00%
Debt Instrument, Interest Rate, Stated Percentage			24.00%
Debt Instrument, Term (Month)			1 year 180 days
Debt Instrument, Convertible, First Customary Conversion Blockers			4.99%
Debt Instrument, Convertible, Second customary conversion blockers			9.99%
Debt Instrument, Unamortized Discount, Total									$ 800,000
Convertible Debt [Member] | Notes [Member] | Maximum [Member]
Debt Instrument, Face Amount			$ 800,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)			$ 1.80
Convertible Debt [Member] | Notes [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)			$ 0.50
Convertible Debt [Member] | January 2019 Notes, Amendment No. 1 [Member]
Debt Instrument, Unamortized Discount, Total								$ 556,000
Gain (Loss) on Extinguishment of Debt, Total								840,000
Long-term Debt, Fair Value		$ 1,473,000
Amortization of Debt Discount (Premium)								$ 77,000
Convertible Debt [Member] | The July 2019 Note [Member]
Debt Instrument, Face Amount		$ 1,000,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger		90.00%
Debt Instrument, Interest Rate, Stated Percentage		24.00%
Amortization of Debt Discount (Premium)				$ 27,000		$ 107,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 694,000
Convertible Debt [Member] | The July 2019 Note [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 1.80
Convertible Debt [Member] | The July 2019 Note [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 0.50

Note 5 - Leases (Details Textua

Note 5 - Leases (Details Textual) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019	Jan. 01, 2019
Operating Lease, Right-of-Use Asset	$ 765,000	$ 765,000	$ 859,000
Operating Lease, Payments		225,000
Operating Lease, Cost	$ 135,000	$ 343,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset				$ 966,000

Note 5 - Leases - Lease Informa

Note 5 - Leases - Lease Information (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Right-of-use operating lease assets, net	$ 765,000	$ 859,000
Non-current lease liability	$ 648,000	$ 761,000
Weighted average remaining lease term (Year)	3 years 255 days
Discount rate	22.00%
Current Liabilities [Member]
Current lease liability	$ 147,000

Note 5 - Leases - Maturities of

Note 5 - Leases - Maturities of Lease Liabilities (Details)	Sep. 30, 2020USD ($)
2020 (remaining)	$ 76,000
2021	310,000
2022	319,000
2023	328,000
2024	139,000
Thereafter
Total lease payments	1,172,000
Less: imputed interest	(377,000)
Present value of operating lease liabilities	$ 795,000

Note 6 - Commitments and Cont_3

Note 6 - Commitments and Contingencies (Details Textual) - USD ($)	May 01, 2020	May 04, 2017	Feb. 29, 2020	Oct. 31, 2017	Sep. 30, 2020	Jul. 13, 2020	Mar. 17, 2020	Dec. 31, 2019
Short Term Investment Minimum						$ 1,000,000	$ 1,000,000	$ 2,000,000
Litigation Related to Strategic Advisory Services [Member]
Loss Contingency, Damages Sought, Value		$ 1,000,000
Loss Contingency, Negotiation Condition Bond				$ 1,000,000
Loss Contingency, Damages Awarded, Value			$ 1,000,000
Gain (Loss) Related to Litigation Settlement, Total			(1,400,000)
Litigation Settlement, Expense			1,000,000
Litigation Settlement Interest			$ 400,000
Agreement with Plaintiff For Reimbursement of Trial Related Expenses [Member]
Litigation Settlement, Expense	$ 111,000
Litigation Settlement Interest	369,000
Loss Contingency, Damages Awarded, Value	$ 480,000
Minimum [Member]
Period Of Warranty On Products (Year)					1 year
Maximum [Member]
Period Of Warranty On Products (Year)					2 years

Note 6 - Commitments and Cont_4

Note 6 - Commitments and Contingencies - Changes in Product Liability Included in Accrued Liabilities (Details)	9 Months Ended
	Sep. 30, 2020USD ($)
Balance	$ 277,000
Warranties issued during the period	62,000
Settlements made during the period	(171,000)
Changes in liability for pre-existing warranties during the period	(20,000)
Balance	$ 148,000

Note 7 - Stockholders' Equity_2

Note 7 - Stockholders' Equity (Details Textual) - USD ($)	Mar. 27, 2020	Dec. 13, 2019	Nov. 12, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	May 19, 2020
Proceeds from Issuance of Common Stock, Net						$ 5,580,000	$ 756,000
Share-based Payment Arrangement, Expense				$ 234,000	$ 253,000	$ 615,000	$ 459,000
Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	1,000,002
Shares Issued, Price Per Share (in dollars per share)	$ 3.50
Proceeds from Issuance of Common Stock	$ 3,500,000
Payments of Stock Issuance Costs	$ 393,000
At The Market Offering Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)						517,740
Proceeds from Issuance of Common Stock						$ 2,785,000
Payments of Stock Issuance Costs						$ 312,000
Maximum Offering Price for Issuance of Common Stock		$ 4,400,000						$ 15,280,313
Commission as Percentage of Gross Proceeds		3.00%
Shares Issued, Average Price Per Share (in dollars per share)						$ 5.38
Proceeds from Issuance of Common Stock, Net						$ 2,473,000
At The Market Offering Agreement [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)			964,130
Proceeds from Issuance of Common Stock			$ 2,771,000
Payments of Stock Issuance Costs			$ 88,000
Shares Issued, Average Price Per Share (in dollars per share)			$ 2.87
Proceeds from Issuance of Common Stock, Net			$ 2,683,000

Note 7 - Stockholders' Equity -

Note 7 - Stockholders' Equity - Stock-based Compensation (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Stock-based compensation	$ 234,000	$ 253,000	$ 615,000	$ 459,000
Cost of Sales [Member]
Stock-based compensation	3,000	1,000	5,000	2,000
Selling and Marketing Expense [Member]
Stock-based compensation	65,000	110,000	106,000	166,000
Research and Development Expense [Member]
Stock-based compensation	36,000	38,000	72,000	75,000
General and Administrative Expense [Member]
Stock-based compensation	$ 130,000	$ 104,000	$ 432,000	$ 216,000

Note 7 - Stockholders' Equity_3

Note 7 - Stockholders' Equity - Option Activity for Stock Option Plans (Details)	9 Months Ended
	Sep. 30, 2020USD ($)$ / sharesshares
Outstanding, options (in shares) | shares	291,807
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 13.96
Granted, options (in shares) | shares	615,500
Granted, weighted average exercise price, options (in dollars per share) | $ / shares	$ 5.92
Forfeited, options (in shares) | shares	(15,158)
Forfeited, weighted average exercise price, options (in dollars per share) | $ / shares	$ 5.13
Outstanding, options (in shares) | shares	892,149
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 8.57
Outstanding, weighted average remaining contractual life, options (Year)	8 years 363 days
Outstanding, aggregate intrinsic value, options | $
Vested and expected to vest, options (in shares) | shares	565,836
Vested and expected to vest, weighted average exercise price, options (in dollars per share) | $ / shares	$ 9.91
Vested and expected to vest, weighted average remaining contractual life, options (Year)	8 years 268 days
Vested and expected to vest, aggregate intrinsic value, options | $
Exercisable, options (in shares) | shares	184,137
Exercisable, weighted average exercise price, options (in dollars per share) | $ / shares	$ 17.05
Exercisable, weighted average remaining contractual life, options (Year)	7 years 242 days
Exercisable, aggregate intrinsic value, options | $

Note 7 - Stockholders' Equity_4

Note 7 - Stockholders' Equity - Warrant Activity (Details)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Outstanding (in shares) | shares	1,716,066
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 25.23
Warrants expired (in shares) | shares
Warrants expired, weighted average exercise price (in dollars per share) | $ / shares
Warrants exercised (in shares) | shares	(599,582)
Warrants exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 2.81
Outstanding (in shares) | shares	1,116,484
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 37.27
Exercisable (in shares) | shares	1,046,631
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 34.42

Note 8 - Major Customers and _2

Note 8 - Major Customers and Accounts Receivable (Details Textual) - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Revenue Benchmark [Member] | Customer 1 [Member]
Concentration Risk, Percentage	22.00%	27.00%	28.00%	29.00%
Revenue Benchmark [Member] | Customer 2 [Member]
Concentration Risk, Percentage	20.00%	13.00%	12.00%	13.00%
Revenue Benchmark [Member] | Customer 3 [Member]
Concentration Risk, Percentage	10.00%	2.00%	12.00%	0.00%
Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk, Percentage			59.00%		53.00%